WO2002078697A1 - Compounds and methods - Google Patents
Compounds and methods Download PDFInfo
- Publication number
- WO2002078697A1 WO2002078697A1 PCT/US2002/009954 US0209954W WO02078697A1 WO 2002078697 A1 WO2002078697 A1 WO 2002078697A1 US 0209954 W US0209954 W US 0209954W WO 02078697 A1 WO02078697 A1 WO 02078697A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- optionally substituted
- ethyl
- triazole
- anilino
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 77
- 238000000034 method Methods 0.000 title claims description 36
- 230000001404 mediated effect Effects 0.000 claims abstract description 11
- SNTWKPAKVQFCCF-UHFFFAOYSA-N 2,3-dihydro-1h-triazole Chemical compound N1NC=CN1 SNTWKPAKVQFCCF-UHFFFAOYSA-N 0.000 claims description 46
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 39
- 125000001424 substituent group Chemical group 0.000 claims description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 15
- -1 substituted Chemical class 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 15
- 241000124008 Mammalia Species 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 230000005764 inhibitory process Effects 0.000 claims description 10
- 239000012453 solvate Substances 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 6
- 125000001041 indolyl group Chemical group 0.000 claims description 6
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims description 5
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 5
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
- 125000006661 (C4-C6) heterocyclic group Chemical group 0.000 claims description 2
- PVPTUASRAVWKGX-UHFFFAOYSA-N 1,2-dihydrotriazol-3-amine Chemical compound NN1NNC=C1 PVPTUASRAVWKGX-UHFFFAOYSA-N 0.000 claims description 2
- ZUWQZGRZWWUZSM-UHFFFAOYSA-N 3-methyl-n-phenyl-5-(2-phenylethyl)-1,2,4-triazol-3-amine Chemical compound N1=NC(CCC=2C=CC=CC=2)=NC1(C)NC1=CC=CC=C1 ZUWQZGRZWWUZSM-UHFFFAOYSA-N 0.000 claims description 2
- CHPKHWDQVPRRQL-UHFFFAOYSA-N 5-(2-cyclohexylethyl)-n-phenyl-1h-1,2,4-triazol-3-amine Chemical compound C1CCCCC1CCC(NN=1)=NC=1NC1=CC=CC=C1 CHPKHWDQVPRRQL-UHFFFAOYSA-N 0.000 claims description 2
- NHGZILMEEFXOPK-UHFFFAOYSA-N 5-(naphthalen-2-ylmethyl)-n-phenyl-1h-1,2,4-triazol-3-amine Chemical compound C=1C=C2C=CC=CC2=CC=1CC(NN=1)=NC=1NC1=CC=CC=C1 NHGZILMEEFXOPK-UHFFFAOYSA-N 0.000 claims description 2
- LLGRAERTVBYAJY-UHFFFAOYSA-N 5-benzyl-n-phenyl-1h-1,2,4-triazol-3-amine Chemical compound C=1C=CC=CC=1CC(NN=1)=NC=1NC1=CC=CC=C1 LLGRAERTVBYAJY-UHFFFAOYSA-N 0.000 claims description 2
- JVFJVXRMJKCALI-UHFFFAOYSA-N ethyl n'-(3-cyclohexylpropanoyl)-n-phenylcarbamimidothioate Chemical compound C=1C=CC=CC=1N=C(SCC)NC(=O)CCC1CCCCC1 JVFJVXRMJKCALI-UHFFFAOYSA-N 0.000 claims description 2
- LUZJWXGOOUDLSQ-UHFFFAOYSA-N n-phenyl-5-(phenylsulfanylmethyl)-1h-1,2,4-triazol-3-amine Chemical compound N=1C(NC=2C=CC=CC=2)=NNC=1CSC1=CC=CC=C1 LUZJWXGOOUDLSQ-UHFFFAOYSA-N 0.000 claims description 2
- TYXUXJRCPQZMKP-UHFFFAOYSA-N n-(4-fluorophenyl)-5-(2-phenylethyl)-1h-1,2,4-triazol-3-amine Chemical compound C1=CC(F)=CC=C1NC1=NNC(CCC=2C=CC=CC=2)=N1 TYXUXJRCPQZMKP-UHFFFAOYSA-N 0.000 claims 2
- GBHBELXYVICFIQ-UHFFFAOYSA-N n-phenyl-5-(1-phenylpropan-2-yl)-1h-1,2,4-triazol-3-amine Chemical compound N=1C(NC=2C=CC=CC=2)=NNC=1C(C)CC1=CC=CC=C1 GBHBELXYVICFIQ-UHFFFAOYSA-N 0.000 claims 2
- JRKPJVFFZOKZFC-UHFFFAOYSA-N ethyl n-(2-propan-2-ylphenyl)-n'-(3-thiophen-2-ylpropanoyl)carbamimidothioate Chemical compound C=1C=CC=C(C(C)C)C=1N=C(SCC)NC(=O)CCC1=CC=CS1 JRKPJVFFZOKZFC-UHFFFAOYSA-N 0.000 claims 1
- NWNBBNXUVCACMH-UHFFFAOYSA-N ethyl n-phenyl-n'-(2-phenylethanethioyl)carbamimidothioate Chemical compound C=1C=CC=CC=1N=C(SCC)NC(=S)CC1=CC=CC=C1 NWNBBNXUVCACMH-UHFFFAOYSA-N 0.000 claims 1
- MGYKVXYDMFZFBU-UHFFFAOYSA-N n-(2-propan-2-ylphenyl)-5-(2-thiophen-2-ylethyl)-1h-1,2,4-triazol-3-amine Chemical compound CC(C)C1=CC=CC=C1NC1=NNC(CCC=2SC=CC=2)=N1 MGYKVXYDMFZFBU-UHFFFAOYSA-N 0.000 claims 1
- VKBINRLXWCTSTG-UHFFFAOYSA-N n-(4-methylphenyl)-5-(naphthalen-2-ylmethyl)-1h-1,2,4-triazol-3-amine Chemical compound C1=CC(C)=CC=C1NC1=NNC(CC=2C=C3C=CC=CC3=CC=2)=N1 VKBINRLXWCTSTG-UHFFFAOYSA-N 0.000 claims 1
- LMYHWIUDSUNKSH-UHFFFAOYSA-N n-phenyl-5-(2-thiophen-2-ylethyl)-1h-1,2,4-triazol-3-amine Chemical compound C=1C=CSC=1CCC(NN=1)=NC=1NC1=CC=CC=C1 LMYHWIUDSUNKSH-UHFFFAOYSA-N 0.000 claims 1
- VVPDJWKZTFWOMS-UHFFFAOYSA-N n-phenyl-5-(thiophen-2-ylsulfanylmethyl)-1h-1,2,4-triazol-3-amine Chemical compound N=1N=C(NC=2C=CC=CC=2)NC=1CSC1=CC=CS1 VVPDJWKZTFWOMS-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 20
- 206010029113 Neovascularisation Diseases 0.000 abstract description 16
- 201000011510 cancer Diseases 0.000 abstract description 14
- 101710181812 Methionine aminopeptidase Proteins 0.000 abstract description 13
- 239000003112 inhibitor Substances 0.000 abstract description 12
- 208000008589 Obesity Diseases 0.000 abstract description 8
- 201000004681 Psoriasis Diseases 0.000 abstract description 8
- 206010038934 Retinopathy proliferative Diseases 0.000 abstract description 8
- 230000033115 angiogenesis Effects 0.000 abstract description 8
- 230000003143 atherosclerotic effect Effects 0.000 abstract description 8
- 201000011066 hemangioma Diseases 0.000 abstract description 8
- 235000020824 obesity Nutrition 0.000 abstract description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract description 8
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 5
- 230000002441 reversible effect Effects 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 description 24
- 239000007787 solid Substances 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 20
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 20
- 239000004480 active ingredient Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 239000000203 mixture Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- 238000003556 assay Methods 0.000 description 12
- 229910052736 halogen Inorganic materials 0.000 description 11
- 150000002367 halogens Chemical class 0.000 description 11
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- NGGMYCMLYOUNGM-CSDLUJIJSA-N fumagillin Chemical class C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)C[C@@]21CO2 NGGMYCMLYOUNGM-CSDLUJIJSA-N 0.000 description 8
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- NGGMYCMLYOUNGM-UHFFFAOYSA-N (-)-fumagillin Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)C=CC=CC=CC=CC(O)=O)CCC21CO2 NGGMYCMLYOUNGM-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HJZLEGIHUQOJBA-UHFFFAOYSA-N cyclohexane propionic acid Chemical compound OC(=O)CCC1CCCCC1 HJZLEGIHUQOJBA-UHFFFAOYSA-N 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 229960000936 fumagillin Drugs 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 5
- RXGJTUSBYWCRBK-UHFFFAOYSA-M 5-methylphenazinium methyl sulfate Chemical compound COS([O-])(=O)=O.C1=CC=C2[N+](C)=C(C=CC=C3)C3=NC2=C1 RXGJTUSBYWCRBK-UHFFFAOYSA-M 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 238000011200 topical administration Methods 0.000 description 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- FHLNBHBQGFIHKH-UHFFFAOYSA-N 2-amino-n-(4-methyl-2-oxochromen-7-yl)-4-methylsulfanylbutanamide Chemical compound CC1=CC(=O)OC2=CC(NC(=O)C(N)CCSC)=CC=C21 FHLNBHBQGFIHKH-UHFFFAOYSA-N 0.000 description 3
- DAKDRBDXRWKBRS-UHFFFAOYSA-N 2-thiophen-2-ylsulfanylacetohydrazide Chemical compound NNC(=O)CSC1=CC=CS1 DAKDRBDXRWKBRS-UHFFFAOYSA-N 0.000 description 3
- JRBJSXQPQWSCCF-UHFFFAOYSA-N 3,3'-Dimethoxybenzidine Chemical compound C1=C(N)C(OC)=CC(C=2C=C(OC)C(N)=CC=2)=C1 JRBJSXQPQWSCCF-UHFFFAOYSA-N 0.000 description 3
- LSSUJBFVEXWEEC-UHFFFAOYSA-N 3-phenylpropanehydrazide Chemical compound NNC(=O)CCC1=CC=CC=C1 LSSUJBFVEXWEEC-UHFFFAOYSA-N 0.000 description 3
- MJPVYTKZYZPIQA-UHFFFAOYSA-N 3-thiophen-2-ylpropanoic acid Chemical compound OC(=O)CCC1=CC=CS1 MJPVYTKZYZPIQA-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 108010008292 L-Amino Acid Oxidase Proteins 0.000 description 3
- 102000007070 L-amino-acid oxidase Human genes 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical compound CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000003899 bactericide agent Substances 0.000 description 3
- KDKYADYSIPSCCQ-UHFFFAOYSA-N but-1-yne Chemical compound CCC#C KDKYADYSIPSCCQ-UHFFFAOYSA-N 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- XNMQEEKYCVKGBD-UHFFFAOYSA-N dimethylacetylene Natural products CC#CC XNMQEEKYCVKGBD-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- PLBWRAWSHVJPTL-JTQLQIEISA-N l-methionine p-nitroanilide Chemical compound CSCC[C@H](N)C(=O)NC1=CC=C([N+]([O-])=O)C=C1 PLBWRAWSHVJPTL-JTQLQIEISA-N 0.000 description 3
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
- 230000007498 myristoylation Effects 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 150000003852 triazoles Chemical group 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- BRWKXKNZRVALNZ-UHFFFAOYSA-N (4-fluorophenyl)thiourea Chemical compound NC(=S)NC1=CC=C(F)C=C1 BRWKXKNZRVALNZ-UHFFFAOYSA-N 0.000 description 2
- SRYLJBWDZZMDSK-UHFFFAOYSA-N (4-methoxyphenyl)thiourea Chemical compound COC1=CC=C(NC(N)=S)C=C1 SRYLJBWDZZMDSK-UHFFFAOYSA-N 0.000 description 2
- PKYCWFICOKSIHZ-UHFFFAOYSA-N 1-(3,7-dihydroxyphenoxazin-10-yl)ethanone Chemical compound OC1=CC=C2N(C(=O)C)C3=CC=C(O)C=C3OC2=C1 PKYCWFICOKSIHZ-UHFFFAOYSA-N 0.000 description 2
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IBXNCJKFFQIKKY-UHFFFAOYSA-N 1-pentyne Chemical class CCCC#C IBXNCJKFFQIKKY-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- MOTOSAGBNXXRRE-UHFFFAOYSA-N 2-phenylsulfanylacetic acid Chemical compound OC(=O)CSC1=CC=CC=C1 MOTOSAGBNXXRRE-UHFFFAOYSA-N 0.000 description 2
- HVAIRLQMYATCKN-UHFFFAOYSA-N 3,4-dihydro-2h-quinoline-1-carbothioamide Chemical compound C1=CC=C2N(C(=S)N)CCCC2=C1 HVAIRLQMYATCKN-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 102100035549 Eukaryotic translation initiation factor 2 subunit 1 Human genes 0.000 description 2
- 101710151743 Eukaryotic translation initiation factor 2 subunit 1 Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical compound CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 125000005530 alkylenedioxy group Chemical group 0.000 description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- IAQRGUVFOMOMEM-UHFFFAOYSA-N but-2-ene Chemical compound CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- SFANHGPMQSFCAU-UHFFFAOYSA-N ethyl n'-(2-propan-2-ylphenyl)carbamimidothioate;hydroiodide Chemical compound I.CCSC(=N)NC1=CC=CC=C1C(C)C SFANHGPMQSFCAU-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000417 fungicide Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical compound CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- LAXNJIWNBHHMDO-UHFFFAOYSA-N s-ethyl-n-phenyl-isothiourea Chemical compound CCS\C(N)=N\C1=CC=CC=C1 LAXNJIWNBHHMDO-UHFFFAOYSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 108091064702 1 family Proteins 0.000 description 1
- 150000000178 1,2,4-triazoles Chemical class 0.000 description 1
- CGHIBGNXEGJPQZ-UHFFFAOYSA-N 1-hexyne Chemical class CCCCC#C CGHIBGNXEGJPQZ-UHFFFAOYSA-N 0.000 description 1
- MCWZNJNWGQPUGL-UHFFFAOYSA-N 1-methyl-1-phenylthiourea Chemical compound NC(=S)N(C)C1=CC=CC=C1 MCWZNJNWGQPUGL-UHFFFAOYSA-N 0.000 description 1
- BOCWTHDHJPOLAY-UHFFFAOYSA-N 2-[[2-[[2-[(2-amino-4-methylsulfanylbutanoyl)amino]acetyl]amino]-4-methylsulfanylbutanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound CSCCC(N)C(=O)NCC(=O)NC(CCSC)C(=O)NC(CCSC)C(O)=O BOCWTHDHJPOLAY-UHFFFAOYSA-N 0.000 description 1
- HLPIHRDZBHXTFJ-UHFFFAOYSA-N 2-ethylfuran Chemical class CCC1=CC=CO1 HLPIHRDZBHXTFJ-UHFFFAOYSA-N 0.000 description 1
- JCCCMAAJYSNBPR-UHFFFAOYSA-N 2-ethylthiophene Chemical class CCC1=CC=CS1 JCCCMAAJYSNBPR-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- MCIIDRLDHRQKPH-UHFFFAOYSA-N 2-methyl-3-phenylpropanoic acid Chemical compound OC(=O)C(C)CC1=CC=CC=C1 MCIIDRLDHRQKPH-UHFFFAOYSA-N 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- 125000006087 2-oxopyrrolodinyl group Chemical group 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 101100072149 Drosophila melanogaster eIF2alpha gene Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- WXHHTBVYQOSYSL-FXQIFTODSA-N Met-Ala-Ser Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O WXHHTBVYQOSYSL-FXQIFTODSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 1
- 108090000192 Methionyl aminopeptidases Proteins 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 101100174763 Mus musculus Galk1 gene Proteins 0.000 description 1
- 229910017852 NH2NH2 Inorganic materials 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 101710192141 Protein Nef Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 238000011122 anti-angiogenic therapy Methods 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000000006 cell growth inhibition assay Methods 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960002152 chlorhexidine acetate Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000007247 enzymatic mechanism Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
- ZJGHEUYKWKTKCH-UHFFFAOYSA-N ethyl 4-(carbamothioylamino)benzoate Chemical compound CCOC(=O)C1=CC=C(NC(N)=S)C=C1 ZJGHEUYKWKTKCH-UHFFFAOYSA-N 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- VUNMENSLIFIRQS-UHFFFAOYSA-N ethyl n'-(2-methyl-3-phenylpropanoyl)-n-(2-propan-2-ylphenyl)carbamimidothioate Chemical compound C=1C=CC=C(C(C)C)C=1N=C(SCC)NC(=O)C(C)CC1=CC=CC=C1 VUNMENSLIFIRQS-UHFFFAOYSA-N 0.000 description 1
- CYTGYYHWIKQBLO-UHFFFAOYSA-N ethyl n'-(2-propan-2-ylphenyl)carbamimidothioate Chemical compound CCSC(=N)NC1=CC=CC=C1C(C)C CYTGYYHWIKQBLO-UHFFFAOYSA-N 0.000 description 1
- MDGDHIMLZYCSAG-UHFFFAOYSA-N ethyl n'-phenylcarbamimidothioate;hydroiodide Chemical compound I.CCSC(N)=NC1=CC=CC=C1 MDGDHIMLZYCSAG-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 102000034345 heterotrimeric G proteins Human genes 0.000 description 1
- 108091006093 heterotrimeric G proteins Proteins 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000004836 hexamethylene group Chemical class [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 108010016686 methionyl-alanyl-serine Proteins 0.000 description 1
- BYGYMIVKNBTVDG-UHFFFAOYSA-N methyl 2-thiophen-2-ylsulfanylacetate Chemical compound COC(=O)CSC1=CC=CS1 BYGYMIVKNBTVDG-UHFFFAOYSA-N 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- QGXRGSGJDCUSQA-UHFFFAOYSA-N n-(2-methylphenyl)-5-(2-phenylethyl)-1h-1,2,4-triazol-3-amine Chemical compound CC1=CC=CC=C1NC1=NNC(CCC=2C=CC=CC=2)=N1 QGXRGSGJDCUSQA-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- FPTWYLLANXWJIK-UHFFFAOYSA-N n-phenyl-5-(2-phenylethyl)-1h-1,2,4-triazol-3-amine Chemical compound N=1C(NC=2C=CC=CC=2)=NNC=1CCC1=CC=CC=C1 FPTWYLLANXWJIK-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000006959 non-competitive inhibition Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000004817 pentamethylene group Chemical class [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 235000012796 pita bread Nutrition 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- SLUHLANJIVXTRQ-UHFFFAOYSA-N pyridin-2-ylthiourea Chemical compound NC(=S)NC1=CC=CC=N1 SLUHLANJIVXTRQ-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- VFIZBHJTOHUOEK-UHFFFAOYSA-N s-ethylisothiourea Chemical compound CCSC(N)=N VFIZBHJTOHUOEK-UHFFFAOYSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 108060007624 small GTPase Proteins 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000006090 thiamorpholinyl sulfone group Chemical group 0.000 description 1
- 125000006089 thiamorpholinyl sulfoxide group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/30—Isothioureas
- C07C335/38—Isothioureas containing any of the groups, X being a hetero atom, Y being any atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- Compounds of this invention are non-peptide, reversible inhibitors of type 2 methionine aminopeptidase, useful in treating conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization and obesity.
- angiogenesis such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization and obesity.
- angiogenesis a process termed angiogenesis (Folkman J. (1974) Adv Cancer Res. 19; 331).
- the new blood vessels induced by tumor cells as their life-line of oxygen and nutrients also provide exits for cancer cells to spread to other parts of the body. Inhibition of this process has been shown to effectively stop the proliferation and metastasis of solid tumors.
- a drug that specifically inhibits this process is known as an angiogenesis inhibitor.
- the anti- angiogenesis therapy (“indirect attack”) has several advantages over the “direct attack” strategies. All the “direct attack” approaches such as using DNA damaging drugs, antimetabolites, attacking the RAS pathway, restoring p53, activating death programs, using aggressive T-cells, injecting monoclonal antibodies and inhibiting telomerase, etc., inevitably result in the selection of resistant tumor cells. Targeting the endothelial compartment of tumors as in the "indirect attack”, however, should avoid the resistance problem because endothelial cells do not exliibit the same degree of genomic instability as tumor cells.
- anti-angiogenic therapy generally has low toxicity due to the fact that normal endothelial cells are relatively quiescent in the body and exhibit an extremely long turnover.
- direct attack target different cell types, there is a great potential for a more effective combination therapy.
- More than 300 angiogenesis inhibitors have been discovered, of which about 31 agents are currently being tested in human trials in treatment of cancers (Thompson, et al., (1999) J Pathol 187, 503).
- TNP-470 a semisynthetic derivative of fumagillin of Aspergillus fuigatus, is among the most potent inhibitors of angiogenesis.
- Fumagillin and TNP-470 have been shown to inhibit type 2 methionine aminopeptidase (hereinafter MetAP2) by irreversibly modifying its active site.
- MetAP2 type 2 methionine aminopeptidase
- the biochemical activity of fumagillin analogs has been shown to correlate to their inhibitory effect on the proliferation of human umbillical vein endothelial cells (HUVEC).
- hMetAP-2-catalyzed cleavage of the initiator methionine of proteins could be essential for releasing many proteins that, after myristoylation, function as important signaling cellular factors involved in cell proliferation.
- Proteins known to be myristoylated include the src family tyrosine kinases, the small GTPase ARF, the HTV protein nef and the subunit of heterotrimeric G proteins.
- a recently published study has shown that the myristoylation of nitric oxide synthase, a membrane protein involved in cell apoptosis, was blocked by fumagillin (Yoshida, et al. (1998) Cancer Res. 58(16), 3751).
- MetAP2-catalyzed release of the glycine-terminal myristoylation substrate is proposed to be an indirect outcome of inhibition of MetAP2-catalyzed release of the glycine-terminal myristoylation substrate.
- MetAP enzymes are known to be important to the stability of proteins in vivo according to the "N-end rule" which suggests increased stability of methionine-cleaved proteins relative to their N-terminal methionine precursors (Varshavsky, A (1996) Proc. Natl. Acad. Sci. U.S.A. 93, 12142). Inhibition of hMetAP2 could result in abnormal presence or absence of some cellular proteins critical to the cell cycle.
- Methionine aminopeptidases are ubiquitously distributed in all living organisms. They catalyze the removal of the initiator methionine from newly translated polypeptides using divalent metal ions as cofactors. Two distantly related MetAP enzymes, type 1 and type 2, are found in eukaryotes, which at least in yeast, are both required for normal growth; whereas only one single MetAP is found in eubacteria (type 1) and archaebacteria (type 2). The N-terminal extension region distinguishes the methionine aminopeptidases in eukaryotes from those in procaryotes.
- a 64-amino acid sequence insertion (from residues 381 to 444 in hMetAP2) in the catalytic C-terminal domain distinguishes the MetAP-2 family from the MetAP- 1 family.
- all MetAP enzymes appear to share a highly conserved catalytic scaffold termed "pita-bread" fold (Bazan, et al. (1994) Proc. Natl. Acad. Sci. U.S.A. 91, 2473), which contains six strictly conserved residues implicated in the coordination of the metal cofactors.
- Mammalian type 2 methionine aminopeptidase has been identified as a bifunctional protein implicated by its ability to catalyze the cleavage of N-terminal methionine from nascent polypeptides (Bradshaw, et al (1998) Trends Biochem. Sci. 23, 263) and to associate with eukaryotic initiation factor 2 ⁇ (eIF-2 ⁇ ) to prevent its phosphorylation (Ray, et al. (1992) Proc. Natl. Acad. Sci. U.S.A. 89, 539). Both the genes of human and rat MetAP2 were cloned and have shown 92% sequence identity (Wu,. et al. (1993) J Biol. Chem.
- the anti-angiogenic compounds, fumagillin and its analogs, have been shown to specifically block the exo-aminopeptidase activity of hMetAP2 without interfering with the formation of the hMetAP2 : eIF2 ⁇ complex (Griffith, et al., (1997) Chem. Biol. 4, 461; Sin, et al. (1997) Proc. Natl. Acad. Sci. U.S.A. 94, 6099). Fumagillin and its analogs inactivate the enzymatic activity of hMetAP2 with a high specificity, which is underscored by the lack of effect of these compounds on the closely related type 1 methionine aminopeptidase
- the present invention is to a novel compound of formula (I), or a pharmaceutically active salt or solvate thereof, and its use in treating conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization and obesity:
- angiogenesis such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization and obesity:
- R! is optionally substituted C j fi alkyl, C 2 alkenyl, C 2 6 alkynyl, optionally substituted Ar-C j 6 alkyl-, optionally substituted Het-C j 6 alkyl-, or optionally substituted C 3 .cycloalkyl-C j 6 alkyl-, provided that when R is optionally substituted Het-C galk l-, and Het is indolyl, benzofuranyl, benzothienyl, benzisoxazolyl, benzisothiazolyl, benzopyrazolyl, or pyrrolo[2,3-c]pyridinyl then the optional substituent is not -(CH2) ⁇ .5CHRI]S ⁇ R.IIR 1 I J -, or the optional substituent is not a 4- to
- R 1 is H or C. ⁇ alkyl
- R ** - * ** * and R * " * - ***** - are independently H, C g alkyl, or together with the nitrogen to which they are attached form a 4- to 6-membered heterocyclic ring which optionally contains one or more additional heteroatoms selected from N, O, and S; provided that when R ⁇ is
- C ⁇ alkyl- the optional substituent cannot be -OR ⁇ , -R4, or -NR ⁇ RS, wherein R ⁇ , R * - * ", and R ⁇ are independently selected from H, C fi alkyl, C 3 alkenyl, C 3 fi alkynyl, Ph-C 0 g alkyl-, Het-C ⁇ alkyl-, or C 3 7 cycloalkyl-C 0 fi alkyl-;
- R- 2 is optionally substituted C alkyl, C 3 fi alkenyl, C 3 6 alkynyl, optionally substituted Ar-C Q g alkyl-, optionally substituted Het-C Q 6 alkyl-, or optionally substituted
- R 3 is H, optionally substituted C ⁇ 6 alkyl, C 3 6 alkenyl, C 3 6 alkynyl, optionally substituted Ar-C Q g alkyl-, optionally substituted Het-C Q 6 alkyl-, optionally substituted C 3 7 cycloalkyl-C 0 6 alkyl-, -C Q 6 alkyl-C(0)X'AB, C Q 6 alkyl-S(0) 2 X'AB, or -C all yl-X'AB, wherein X' is O, S, C or N, and wherein A and B are independently absent, H, optionally substituted C ⁇ 6 alkyl, C 3 6 alkenyl, C 3 6 alkynyl, optionally substituted Ar-C Q fi alkyl-, optionally substituted Het-C Q _ 6 alkyl-, or C cycloalkyl-C 0 g alkyl-; provided that the compound is not
- the present invention is to a method of treating conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization and obesity by administering a compound of formula (LA), or a pha ⁇ naceutically acceptable salt or solvate thereof
- angiogenesis such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization and obesity
- R! is optionally substituted C ⁇ 6 alkyl, C 2 g alkenyl, C 2 g alkynyl, optionally substituted Ar-C ⁇ -6 alkyl-, optionally substituted Het-C ⁇ -6 alkyl-, or optionally substituted
- R2 is optionally substituted C ⁇ alkyl, C 3 . 6 alkenyl, C 3 . 6 alkynyl, optionally substituted Ar-Co- ⁇ alkyl, optionally substituted Het-C 0 - 6 alkyl-, or optionally substituted C 3 .
- R 3 is H, optionally substituted C ⁇ _ s alkyl, C 3-6 alkenyl, C 3-6 alkynyl, optionally substituted Ar-Co- ⁇ alkyl-, optionally substituted Het-Co-ealkyl-, optionally substituted -C 3-7 cycloalkyl-C 0 - 6 alkyl-, -C 0 .6alkyl-C(O)X'AB, or -C 0 - 6 alkyl-S(O)2XAB, -Co- ⁇ alkyl-X'AB, wherein X' is O, S, C or N and wherein A and B are independently absent, H, optionally substituted C ⁇ _ 6 alkyl, C 3-6 alkenyl, C 3 .
- the present invention is to a method of inhibiting MetAP2 in the treatment of angiogenesis-mediated diseases, all in mammals, preferably humans, comprising administering to such mammal in need thereof, a compound of formula (LA), or a pharmaceutically active salt or solvate thereof.
- the present invention is to a pharmaceutical composition comprising a compound of formula (I) or formula (LA) and a pharmaceutically acceptable carrier therefor.
- the pharmaceutical compositions of the present invention are used for treating MetAP2-mediated diseases.
- the present invention is to novel intermediates useful in the preparation of the compounds of this invention.
- substituted 1,2,4-triazoles of formula (I) and formula (LA) are inhibitors of MetAP2. It has also now been discovered that selective inhibition of MetAP2 enzyme mechanisms by treatment with the inhibitors of formula (I) and formula (LA), or a pharmaceutically acceptable salt or solvate thereof, represents a novel therapeutic and preventative approach to the treatment of a variety of disease states, including, but not limited to, cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization and obesity.
- the term "Ph” represents a phenyl ring.
- C ⁇ .6alkyl as used herein at all occurrences means a substituted and unsubstituted, straight or branched chain radical of 1 to 6 carbon atoms, unless the chain length is limited thereto, including, but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and t-butyl, pentyl, n-pentyl, isopentyl, neopentyl and hexyl and the simple aliphatic isomers thereof.
- any C 1-6 alkyl group may be optionally substituted independently by one or more of -OR , -R4, -NR4R5, -S R .
- C 0 alkyl means that no alkyl group is present in the moiety.
- Ph-COalkyl- is equivalent to Ph.
- C 3-7 cycloalkyl as used herein at all occurrences means substituted or unsubstituted cyclic radicals having 3 to 7 carbons, including but not limited to cyclopropyl, cyclopentyl, cyclohexyl and cycloheptyl radicals.
- C 2- 6alkenyl as used herein at all occurrences means an alkyl group of 2 to 6 carbons wherein a carbon-carbon single bond is replaced by a carbon-carbon double bond.
- C 2 . 6 alkenyl includes ethylene, 1-propene, 2-propene, 1-butene, 2-butene, isobutene and the several isomeric pentenes and hexenes. Both cis and trans isomers are included within the scope of this invention.
- any C 2-6 alkenyl group may be independently, optionally substituted by one or more of Ph-C 0 .6alkyl-, Het-Co- ⁇ alkyl-, C ⁇ . 6 alkyl, C ⁇ _ 6 alkoxy-, C ⁇ . 6 alkyl-S-, Ph-C 0- 6alkoxy-, Het-Co- ⁇ alkoxy-, HO-, R 4 R -, Het-S-C 0 . 6 alkyl-, Ph-S-C 0 . 6 alkyl-, HO(CH 2 ) ⁇ -6 -, R4R5 N (CH 2 ) 2- 6-, R4R5N(CH 2 ) 2 .
- C 2 - 6 al ynyl as used herein at all occurrences means an alkyl group of 2 to 6 carbons wherein one carbon-carbon single bond is replaced by a carbon-carbon triple bond.
- C 2-6 alkynyl includes acetylene, 1-propyne, 2-propyne, 1-butyne, 2-butyne, 3-butyne and the simple isomers of pentyne and hexyne.
- any C 2 - 6 alkynyl group may be independently, optionally substituted by one or more of Ph-Co- ⁇ alkyl-, Het-Co- ⁇ alkyl-, C ⁇ aHcyl-, C ⁇ galkoxy-, C ⁇ . 6 alkyl-S-, Ph-C 0 . 6 alkoxy-, Het-C 0 . 6 alkoxy- 5 HO-, R 4 R5N-, Het-S-C 0 . 6 alkyl-, Ph-S-C 0-6 alkyl-, HO(CH 2 )i -6 -, R4 5N(CH 2 ) 2 .6-, R 4 R5N(CH 2 ) 2 . 6 0-, 6C0 2 (CH 2 )O-6-, R 6 C0 2 (CH 2 ) ⁇ -6 ⁇ -, R 6 S ⁇ 2(CH2) ⁇ -6 -, -CF3, -OCF3, or halogen.
- alkoxy is used herein at all occurrences to mean a straight or branched chain radical of 1 to 6 carbon atoms, unless the chain length is limited thereto, bonded to an oxygen atom, including, but not limited to, methoxy, ethoxy, n- propoxy, isopropoxy, and the like.
- hetero or “heteroatom” as used herein interchangeably at all occurrences mean oxygen, nitrogen and sulfur.
- halo or halogen as used herein interchangeably at all occurrences mean F, CI, Br, and I.
- C 0 denotes the absence of the substituent group immediately following; for instance, in the moiety PhCo- ⁇ alkyl-, when C is 0, the substituent is phenyl.
- Ar or "aryl” as used herein interchangeably at all occurrences mean phenyl and naphthyl, optionally substituted by one or more of Ph-C Q 6 alkyl-, Hef-C 0 6 alkyl-, C j 6 alkyl, C. _ g alkoxy-, C ⁇ alkyl-S-, Ph-C o g alkoxy-, Het'-Co- 6 alkoxy-, -OH, -NR 4 R5,
- Het or "heterocyclic” as used herein interchangeably at all occurrences, mean a stable 5- to 7-membered monocyclic, a stable 7- to 10-membered bicyclic, or a stable 11- to 18-membered tricyclic heterocyclic ring, all of which are either saturated or unsaturated, and consist of carbon atoms and from one to three heteroatoms selected from the group consisting of N, O and S, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quatemized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
- the heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure.
- Het may be optionally substituted with one or more of Ph-C 0 - 6 alkyl-, Hetf- w alkyl-, C 1-6 alkyl, C ⁇ alkoxy-, C ⁇ . 6 alkyl-S-, Ph-C 0 . 6 alkoxy-, Hef-Co- ⁇ alkoxy-, -OH, -NR 4 R5, Hef-S-Co.
- Preferred optional substituents on Het are C ⁇ -6 alkyl, C w alkoxy-, C w al yl-S-, halogen, -CF3, -OCF3, -CN, or -NR 4 R5.
- Het' is defined as for Het and may be optionally substituted by one or more of C 1-6 alkyl, Q ⁇ alkoxy-, -OH, -(CH2) 1-6 NR R5, -0(CH 2 ) I . 6 NR 4 R5, -C0 2 R 6 , CF3, or halogen.
- heterocycles include, but are not limited to piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, pyridinyl, pyrazinyl, oxazolidinyl, oxazolinyl, oxazolyl, isoxazolyl, morpholinyl, thiazolidinyl, thiazolinyl, thiazolyl, quinuclidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, benzoxazolyl, furyl, pyranyl, tetrahydrofuryl, t
- Compounds of this invention of formula (I), do not include compounds wherein R 2 is optionally substituted Het-Cnalkyl-, and Het is indolyl, benzofuranyl, benzothienyl, benzisoxazolyl, benzothiozolylor benzopyrazolyl, and the optional substituent is -(CH 2 ) 2 NR4R5.
- a moiety when a moiety is “optionally substituted” the moiety may have one or more optional substituents, each optional substituent being independently selected.
- substituents each optional substituent being independently selected.
- hetero or “heteroatom” as used herein interchangeably at all occurrences mean oxygen, nitrogen and sulfur.
- halo or halogen as used herein interchangeably at all occurrences mean F, CI, Br, and I.
- CO denotes the absence of the substituent group immediately following; for instance, in the moiety ArCo- ⁇ alkyl-, when C is 0, the substituent is Ar, e.g., phenyl.
- ArCo- ⁇ alkyl- when the moiety ArCo- ⁇ alkyl- is identified as a specific aromatic group, e.g., phenyl, it is understood that C is 0.
- R* is optionally substituted C 2-6 alkyl, C 3 . 6 alkenyl, C 3-6 alkynyl, optionally substituted Ar-C 0- 6alkyl-, optionally substituted Het-C 0- 6alkyl-, or optionally substituted C 3-7 cycloalkyl-Co. 6 alkyl-.
- R- * * is Ar-Co ⁇ alkyl- or optionally substituted Het-C 0 - 6 alkyl-. More preferably Rp is Ar-C2alkyl- or optionally substituted Het-C2alkyl-. Most preferably R! is phenethyl, optionally substituted ethylfuran or optionally substituted ethylthiophene. When R! is Ar-C2alk l- or Het-C2alkyl-, the alkyl chain is directly attached to the 5-position of the triazole.
- R 2 is optionally substituted C 1-6 alkyl, C 3-6 alkenyl, C 3 . 6 alkynyl, optionally substituted Ar-Co- ⁇ alkyl-, optionally substituted Het-C 0 _ 6 alkyl-, or optionally substituted C 3-7 cycloalkyl-C 0 - 6 alkyl-.
- R 2 is optionally substituted Ar-C 0-6 alkyl-. More preferably R 2 is optionally substituted Ar-C()alkyl-, wherein the optional substituent is either in the ortho position or the para position.
- R 2 is optionally substituted Ar-C ⁇ alkyl-, wherein the optional substituent is ortho C ⁇ . 6 alkyl, preferably branched C ⁇ -6 alkyl, most preferably isopropyl.
- R3 is H, optionally substituted C 1-6 alkyl, C 3 . 6 alkenyl, C 3 . 6 alkynyl, optionally substituted Ar-C 0-6 alkyl-, optionally substituted Het-C 0-6 alkyl-, optionally substituted C 3 . 7 cycloalkyl-Co.
- R3 is hydrogen or -C 0 . 6 allyl-C(O)X'AB. More preferably R ⁇ is hydrogen or
- R4, R-5, and R ⁇ are independently selected from H-, C 2 - 6 alkyl, C 3 . 6 alkenyl, C 3 . 6 alkynyl, Ph-Co- ⁇ alkyl-, Het-C 0 - 6 alkyl-, or C 3 . 7 cycloalkyl-Co- 6 alkyl-.
- pharmaceutically acceptable salts of formula (I) and formula (LA) include, but are not limited to, salts with inorganic acids such as hydrochloride, sulfate, phosphate, diphosphate, hydrobromide, and nitrate, or salts with an organic acid such as malate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate, p-toluenesulfonate, palmitate, salicylate, and stearate.
- inorganic acids such as hydrochloride, sulfate, phosphate, diphosphate, hydrobromide, and nitrate
- an organic acid such as malate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate, p-toluenesulfonate, palmitate, salicylate, and stearate.
- the compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms.
- the stereocenters may be (R), (S) or any combination of R and S configuration, for example, (R,R), (R,S), (S,S) or (S,R). All of these compounds are within the scope of the present invention.
- Novel intermediates useful in making compounds of this invention are as follows: 1 -(3 -Cyclohexyl-propanoyl)-2-ethyl-3 -phenyl-isothiourea; l-(3-(2-thienyl)-propanoyl)-2-ethyl-3-(2-isopropylphenyl)-isothiourea; 1 -(2-Methyl-3 -phenyl-propanoy l)-2-ethyl-3 -(2-isopropylphenyl)-isothiourea; 1 -(3 -(2-thienyl)-propanoyl)-2-ethy 1-3 -phenyl-isothiourea; and 1 -(2-pheny lthio-acetyl)-2-ethyl-3 -phenyl-isothiourea.
- a thiourea (such as l-(2-methylphenyl)thiourea, l-(4-methylphenyl)-thiourea,
- the S-ethylisothiourea could be acylated with a carboxylic acid (such as 2-methyl-3-phenyl-propanoic acid, 3-cyclohexylpropionic acid, 3-(2-thienyl)propanoic acid, phenylsulfanyl-acetic acid) under standard coupling conditions to afford the amide.
- a carboxylic acid such as 2-methyl-3-phenyl-propanoic acid, 3-cyclohexylpropionic acid, 3-(2-thienyl)propanoic acid, phenylsulfanyl-acetic acid
- compositions are administered in conventional dosage forms prepared by combining a compound of this invention of formula (I) or (IA) ("active ingredient”) in an amount sufficient to treat cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization or obesity ("MetAp2-mediated disease states") with standard pha ⁇ naceutical carriers or diluents according to conventional procedures well known in the art. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation.
- the pharmaceutical ca ⁇ ier employed may be, for example, either a solid or liquid.
- solid earners are lactose, te ⁇ a alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like.
- liquid carriers are syrup, peanut oil, olive oil, water and the like.
- the ca ⁇ ier or diluent may include time delay material well known to the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax.
- time delay material well known to the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax.
- a wide variety of pharmaceutical forms can be employed.
- the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge.
- the amount of solid carrier will vary widely but preferably will be from about 25 mg to about 1000 mg.
- the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampule or nonaqueous liquid suspension.
- the active ingredient may also be administered topically to a mammal in need of treatment or prophylaxis of MetAP2-mediated disease states.
- the amount of active ingredient required for therapeutic effect on topical administration will, of course, vary with the compound chosen, the nature and severity of the disease state being treated and the mammal undergoing treatment, and is ultimately at the discretion of the physician.
- a suitable dose of an active ingredient is 1.5 mg to 500 mg for topical administration, the most prefe ⁇ ed dosage being 1 mg to 100 mg, for example 5 to 25 mg administered two or three times daily.
- topical administration non-systemic administration and includes the application of the active ingredient externally to the epidermis, to the buccal cavity and instillation of such a compound into the ear, eye and nose, and where the compound does not significantly enter the blood stream.
- systemic administration is meant oral, intravenous, inrraperitoneal and intramuscular administration.
- an active ingredient may be administered alone as the raw chemical, it is preferable to present it as a pharmaceutical formulation.
- the active ingredient may comprise, for topical administration, from 0.001% to 10% w/w, e.g. from 1% to 2% by weight of the formulation although it may comprise as much as 10% w/w but preferably not in excess of 5% w/w and more preferably from 0.1% to 1% w/w of the formulation.
- the topical formulations of the present invention both for veterinary and for human medical use, comprise an active ingredient together with one or more acceptable ca ⁇ ier(s) therefor and optionally any other therapeutic ingredient(s).
- Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose.
- Drops according to the present invention may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous or alcoholic solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a surface active agent.
- the resulting solution may then be clarified by filtration, transfe ⁇ ed to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-100°C for half an hour.
- the solution may be sterilized by filtration and transferred to the container by an aseptic technique.
- bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%).
- Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol.
- Lotions according to the present invention include those suitable for application to the skin or eye.
- An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops.
- Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil.
- Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy basis.
- the basis may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives, or a fatty acid such as stearic or oleic acid together with an alcohol such as propylene glycol.
- the formulation may incorporate any suitable surface-active agent such as an anionic, cationic or non-ionic surfactant such as esters or polyoxyethylene derivatives thereof.
- suitable surface-active agent such as an anionic, cationic or non-ionic surfactant such as esters or polyoxyethylene derivatives thereof.
- Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silicaceous silicas, and other ingredients such as lanolin, may also be included.
- the active ingredient may also be administered by inhalation.
- inhalation is meant intranasal and oral inhalation administration.
- Appropriate dosage forms for such administration such as an aerosol formulation or a metered dose inhaler, may be prepared by conventional techniques.
- the daily dosage amount of the active ingredient administered by inhalation is from about 0.1 mg to about 100 mg per day, preferably about 1 mg to about 10 mg per day.
- this invention relates to a method of treating cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization or obesity, all in mammals, preferably humans, which comprises administering to such mammal an effective amount of a MetAP2 inhibitor, in particular, a compound of this invention.
- a MetAP2 inhibitor in particular, a compound of this invention.
- treating is meant either prophylactic or therapeutic therapy.
- Such compound can be administered to such mammal in a conventional dosage form prepared by combining the compound of this invention with a conventional pharmaceutically acceptable ca ⁇ ier or diluent according to known techniques.
- the fo ⁇ n and character of the pharmaceutically acceptable ca ⁇ ier or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables.
- the compound is administered to a mammal in need of treatment for cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization or obesity, in an amount sufficient to decrease symptoms associated with these disease states.
- the route of administration may be oral or parenteral.
- parenteral as used herein includes intravenous, intramuscular, subcutaneous, intra-rectal, intravaginal or intraperitoneal administration.
- the subcutaneous and intramuscular forms of parenteral administration are generally prefe ⁇ ed.
- the daily parenteral dosage regimen will preferably be from about 30 mg to about 300 mg per day of active ingredient.
- the daily oral dosage regimen will preferably be from about 100 mg to about 2000 mg per day of active ingredient.
- the optimal quantity and spacing of individual dosages of a compound of this invention will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular mammal being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of the compound given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.
- Example 4 Preparation of 3-(4-methyl-anilino -5-[2-(phenyl ethyl]-1.2.4-triazole Following the procedure of Example 2(a)-2(b) except l-(4-methylphenyl)-thiourea was substituted for l-(2-isopropylphenyl)thiourea in step 2(a) the title compound was prepared as a white solid (18%). MS (ESI) 279.0 (M+H)+. IH-NMR (400MHz, d4-MeOH): ⁇ 2.44 (s, 3H), 2.91-3.09 (m, 4H), 7.07 (m, 2H), 7.12-7.29 (m, 7H).
- Example 6 Preparation of 3-(4-fluoro-anilino ' )-5-[2-(phenyl)ethyl1-1.2.4-triazole Following the procedure of Example 2(a)-2(b) except 1 -(4-fluoro-phenyl)thiourea was substituted for l-(2-isopropylphenyl)thiourea in step 2(a) the title compound was prepared as a white solid (31%). MS (ESI) 283.2 (M+H)+.
- Example 8 Preparation of 3-anilino-3-methyl-5-[2-(phenyl)ethyl]-1.2.4-triazole Following the procedure of Example 2(a)-2(b) except 1 -methyl- 1-phenylthiourea was substituted for l-(2-isopropylphenyl)thiourea in step 2(a) the title compound was prepared as a white solid (45%). MS (ESI) 279.0 (M+H)+. IH-NMR (400MHz, d4-MeOH): ⁇ 2.92- 2.94 (m, 2H), 3.00-3.03 (m, 2H), 3.40 (s, 3H), 7.1 3 . 7 .38 (m, 10H).
- Example 9 Preparation of 1 -(5 -phenethyl-4H- [ 1 ,2,4 " ltriazol-3 -ylV 1.2.3.4-tetrahydro-quinoline Following the procedure of Example 2(a)-2(b) except 3,4-dihydro-2H-quinoline-l- carbothioic acid amide was substituted for l-(2-isopropylphenyl)thiourea in step 2(a) the title compound was prepared as a white solid (32%). MS (ESI) 305.4 (M+H)+.
- Example 13 Preparation of 3- 2-isopropyl-anilino)-5-r2-(2-thienyl ethyl "
- S-ethyl-l-(2-isopropylphenyl)- isothiourea hydroiodide was substituted for S-ethyl-1-phenylisothiourea hydroiodide and 3- (2-thienyl)propanoic acid was substituted for 3-cyclohexylpropionic acid in step 12(a) the title compound was prepared as a white solid (3%).
- Example 14 Preparation of 3-anilino-5-[ 1 -methyl-2-(phenyl ethyl]- 1.2.4-triazole Following the procedure of Example 12(a)-2(b) except 2-methy 1-3 -phenyl-propanoic acid was substituted for 3-cyclohexylpropionic acid in step 12(a) the title compound was prepared as a white solid (32%). MS (ESI) 279.0 (M+H)+.
- the hMetAP2 activity can be measured by direct spectrophotometric assay methods using alternative substrates, L-methionine-p-nitroanilide (Met-pNA) and L-methionine-7- amido-4-methylcoumarin (Met-AMC).
- Method-pNA L-methionine-p-nitroanilide
- Metal-AMC L-methionine-7- amido-4-methylcoumarin
- the formation of -nitroaniline (pNA) or 7-amido- 4-methylcoumarin (AMC) was continuously monitored by increasing absorbance or fluorescence at 405 nm and 460 nm, respectively, on a corresponding plate reader. All assays were carried out at 30°C.
- the fluorescence or spectrophotometric plate reader was calibrated using authentic pNA and AMC from Sigma, respectively.
- each 50 ⁇ L assay solution contained 50 mM Hepes.Na-f- (pH 7.5), 100 mMNaCl, 10-lOOnM purified hMetAP2 enzyme, and varying amounts of Met-AMC (in 3% DMSO aqueous solution) or Met-pNA. Assays were initiated with the addition of substrate and the initial rates were corrected for the background rate determined in the absence of hMetAP2.
- Coupled Spectrophotometric Assays of hMetAP2 Coupled Spectrophotometric Assays of hMetAP2:
- the methionine aminopeptidase activity of hMetAP2 can also be measured spectrophotometrically by monitoring the free L-amino acid formation.
- the release of N- terminal methionine from a tripeptide (Met-Ala-Ser, Sigma) or a tetrapeptide (Met-Gly- Met-Met, Sigma) substrate was assayed using the L-amino acid oxidase (AAO) / horse radish peroxidase (HRP) couple (eq. l-3a,b).
- H202 hydrogen peroxide
- a typical assay contained 50 mM Hepes.Na+, pH 7.5, 100 mM NaCl, 10 ⁇ M CoC12, 1 mM o-Dianisidine or 50 ⁇ M Amplex Red, 0.5 units of HRP (Sigma), 0.035 unit of AAO (Sigma), 1 nM hMetAP2, and varying amounts of peptide substrates. Assays were initiated by the addition of hMetAP2 enzyme, and the rates were corrected for the background rate determined in the absence of hMetAP2.
- v is the initial velocity
- N is the maximum velocity
- Ka is the apparent Michaelis constant
- I is the inhibitor concentration
- A is the concentration of variable substrates.
- Kis and Kii represent the apparent slope and intercept inhibition constants, respectively.
- Cell growth inhibition assays The ability of MetAP2 inhibitors to inhibit cell growth was assessed by the standard XTT microtitre assay. XTT, a dye sensitive to the pH change of mitochondria in eukaryotic cells, is used to quantify the viability of cells in the presence of chemical compounds. Cells seeded at a given number undergo approximately two divisions on average in the 72 hours of incubation.
- this population of cells is in exponential growth at the end of the incubation period; the mitochondrial activity of these cells is reflected in the spectrophotometric readout (A450). Viability of a similar cell population in the presence of a given concentration of compound is assessed by comparing the A450 reading from the test well with that of the control well.
- Flat-bottomed 96-well plates are seeded with appropriate numbers df cells (4-6 x 103 cells/well in a volume of 200 ul) from trypsinized exponentially growing cultures, h the case of HUVECs, the wells are coated with matrigel prior to establishing the cultures. To "blank" wells is added growth medium only. Cells are incubated overnight to permit attachment.
- the compounds of this invention show MetAP2 inhibitor activity having IC50 values in the range of 0.0001 to 100 uM.
- the full structure/activity relationship has not yet been established for the compounds of this invention.
- one of ordinary skill in the art can utilize the present assays in order to determine which compounds of this invention are inhibitors of MetAP2 and which bind thereto with an IC50 value in the range of 0.0001 to 100 uM.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02723701A EP1381360A4 (en) | 2001-03-29 | 2002-03-28 | Compounds and methods for inhibiting metap2 in mammals |
JP2002576963A JP2005508841A (en) | 2001-03-29 | 2002-03-28 | Compounds and methods |
US10/473,103 US20040116490A1 (en) | 2002-03-28 | 2002-03-28 | Compounds and methods |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27956301P | 2001-03-29 | 2001-03-29 | |
US60/279,563 | 2001-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002078697A1 true WO2002078697A1 (en) | 2002-10-10 |
Family
ID=23069522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/009954 WO2002078697A1 (en) | 2001-03-29 | 2002-03-28 | Compounds and methods |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1381360A4 (en) |
JP (1) | JP2005508841A (en) |
WO (1) | WO2002078697A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2858617A1 (en) * | 2003-08-06 | 2005-02-11 | Inst Nat Sante Rech Med | NOVEL 4 ', 4'-DITHIOBIS- (3-AMINOBUTANE-1-SULFONATE-1-SULFONATES) DERIVATIVES AND COMPOSITIONS CONTAINING SAME |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5177095A (en) * | 1990-02-13 | 1993-01-05 | Merck & Co., Inc. | Triazole angiotensin II antagonists incorporating a substituted benzyl element |
US5411980A (en) * | 1989-07-28 | 1995-05-02 | Merck & Co., Inc. | Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists |
US5436259A (en) * | 1991-05-10 | 1995-07-25 | Merck & Co., Inc. | Substituted 1,2,4-triazolin-3-one compounds bearing acidic functional groups as balanced angiotensin II antagonists |
US5489598A (en) * | 1994-06-08 | 1996-02-06 | Warner-Lambert Company | Cytoprotection utilizing aryltriazol-3-thiones |
US5750545A (en) * | 1993-07-23 | 1998-05-12 | The Green Cross Corporation | Triazole derivative and pharmaceutical use thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987001706A2 (en) * | 1985-09-12 | 1987-03-26 | The Upjohn Company | C20 through c26 amino steroids |
US6080772A (en) * | 1995-06-07 | 2000-06-27 | Sugen, Inc. | Thiazole compounds and methods of modulating signal transduction |
US5798374A (en) * | 1995-06-07 | 1998-08-25 | Sugen Inc. | Methods of inhibiting phosphatase activity and treatment of disorders associated therewith |
US5760246A (en) * | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
US6207704B1 (en) * | 1997-06-09 | 2001-03-27 | Massachusetts Institute Of Technology | Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof |
CO5011105A1 (en) * | 1997-12-22 | 2001-02-28 | Novartis Ag | ORGANIC COMPOUNDS TO TREAT OBESITY AND RELATED DISORDERS, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND AND PROCESSES FOR THEIR PREPARATION |
FR2792314B1 (en) * | 1999-04-15 | 2001-06-01 | Adir | NOVEL AMINOTRIAZOLE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
DE19922443A1 (en) * | 1999-05-07 | 2000-11-09 | Basf Ag | Use of dopamine D3 receptor ligands in the manufacture of drugs for the treatment of renal dysfunction |
AU7989400A (en) * | 1999-10-01 | 2001-05-10 | Smithkline Beecham Corporation | Compounds and methods |
ES2306671T3 (en) * | 1999-10-07 | 2008-11-16 | Amgen Inc. | TRIAZINE QUINASA INHIBITORS. |
-
2002
- 2002-03-28 WO PCT/US2002/009954 patent/WO2002078697A1/en active Application Filing
- 2002-03-28 EP EP02723701A patent/EP1381360A4/en not_active Withdrawn
- 2002-03-28 JP JP2002576963A patent/JP2005508841A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5411980A (en) * | 1989-07-28 | 1995-05-02 | Merck & Co., Inc. | Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists |
US5177095A (en) * | 1990-02-13 | 1993-01-05 | Merck & Co., Inc. | Triazole angiotensin II antagonists incorporating a substituted benzyl element |
US5436259A (en) * | 1991-05-10 | 1995-07-25 | Merck & Co., Inc. | Substituted 1,2,4-triazolin-3-one compounds bearing acidic functional groups as balanced angiotensin II antagonists |
US5750545A (en) * | 1993-07-23 | 1998-05-12 | The Green Cross Corporation | Triazole derivative and pharmaceutical use thereof |
US5489598A (en) * | 1994-06-08 | 1996-02-06 | Warner-Lambert Company | Cytoprotection utilizing aryltriazol-3-thiones |
Non-Patent Citations (3)
Title |
---|
DATABASE CAPLUS [online] 1975, WAGNER ET AL.: "Reaction of 2,4-dioxo-3,4-dihydro-2H-1,3-benzoxazines and analogous thioxo and imino compounds with hydrazines", XP002972624, accession no. STN Database accession no. 1975:497141 * |
DATABASE CAPLUS [online] 1976, STEIN J.: "'N-substituted amino-1,2,4-triazoles from 2-amino-1,3,4,oxadiazoles and secondary amines", XP002972625, accession no. STN Database accession no. 1977:43626 * |
See also references of EP1381360A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP1381360A4 (en) | 2009-12-02 |
JP2005508841A (en) | 2005-04-07 |
EP1381360A1 (en) | 2004-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7304082B2 (en) | 1,2,4-triazole derivatives, compositions, process of making and methods of use | |
US20040116495A1 (en) | Compounds and methods | |
US20030220371A1 (en) | Compounds and methods | |
AU725696B2 (en) | Bicyclic inhibitors of protein farnesyl transferase | |
JP4855368B2 (en) | Malonyl-CoA decarboxylase inhibitor useful as a metabolic regulator | |
JP4413781B2 (en) | Non-nucleoside reverse transcriptase inhibitors | |
US20070135367A1 (en) | Method for controlling sr protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control sr protein activity | |
JP4727579B2 (en) | Cyanamide compounds useful as malonyl-CoA decarboxylase inhibitors | |
US20040192914A1 (en) | Compounds and methods | |
WO2005039564A1 (en) | Phthalimide compounds useful as protein kinase inhibitors | |
WO1999061440A1 (en) | Novel substituted imidazole compounds | |
KR20010025087A (en) | Novel 2-Alkyl Substituted Imidazole Compounds | |
WO2003051906A2 (en) | Compounds and methods | |
US20040116490A1 (en) | Compounds and methods | |
WO2002005804A1 (en) | Compounds and methods | |
US20060247280A1 (en) | Compounds and methods | |
EP1381360A1 (en) | Compounds and methods for inhibiting metap2 in mammals | |
WO2012149093A1 (en) | 2-guanidino-4-oxo-imidazoline derivatives as antimalarial agents, synthesis and methods of use thereof | |
US9034888B2 (en) | Substituted 2-imidazolidones and analogs | |
WO2001036404A1 (en) | Compounds and methods | |
US6858617B2 (en) | Substituted imidazole compounds | |
US20050222212A1 (en) | Compounds and methods | |
US20080293722A1 (en) | Ion Channel Modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002576963 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002723701 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002723701 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10473103 Country of ref document: US |